Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 7 Lymphoma, Follicular 7 Bronchiolitis Obliterans Syndrome 7 Pruritus 5 Arthritis, Rheumatoid 5 Plaque, Amyloid 1 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1 Cholangiocarcinoma 1 Arthritis, Psoriatic 1 Adenocarcinoma 1

Interventions

Rituximab 416 Cyclophosphamide 348 Vincristine 173 Prednisone 172 Doxorubicin 168 Etoposide 160 Peripheral Blood Stem Cell Transplantation 114 Filgrastim 108 Lenalidomide 97 fludarabine phosphate 96 Radiotherapy 80 Cytarabine 80 Gemcitabine 73 Melphalan 66 Mycophenolic Acid 64 Cyclosporine 60 Methotrexate 59 Busulfan 57 Ifosfamide 55 Carmustine 55 fludarabine 50 Tacrolimus 50 Whole-Body Irradiation 49 Carboplatin 49 polatuzumab vedotin 44 Oxaliplatin 44 Dexamethasone 44 Antilymphocyte Serum 42 ibrutinib 40 Bendamustine Hydrochloride 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large B-Cell, Diffuse × tofacitinib × Clear all

NCT05348213 2024-10-23

R-ICE+X

Ruijin Hospital

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡